

APR 17 2002

SECTION 7  
510(k) SUMMARY

---

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The contents of this 510(k) summary have been provided in conformance with 21 CFR §807.92.

**Date:** March 15, 2002

**Common/Usual Name:** Hemofiltration System

**Trade/Proprietary Name:** NxStage™ Therapy System

**Classification Name & Device Classification:** Dialyzer, High Permeability with or without Dialysate System; Class II

**Product Code:** KDI

**21 CFR Ref.:** 876.5860

**Device Panel:** Gastroenterology-Urology (GU)/Gastro-Renal (GRDB)

**510(k) Sponsor & Owner/Operator:** NxStage Medical, Inc  
439 South Union St, Suite 501  
South Lawrence, MA 01843  
Owner/Operator No. 9045797

**Contact Person:** Norma LeMay  
Sr. Regulatory Specialist

**Device Description:**

The NxStage Therapy System, consisting of hardware, software and a sterile disposable cartridge, is indicated for treatment of renal failure or fluid overload using hemofiltration and/or ultrafiltration. All treatments must be administered by a health care provider, under physician prescription.

**Substantial Equivalence:**

This submission is a Special 510(k) Device Modification as described in FDA's guidance document entitled "The New 510(k) Paradigm - Alternate Approaches to Demonstrating Substantial Equivalence in Pre-Market Notifications." In support of this 510(k), NxStage Medical has provided certification of compliance to 21 CFR 820.30 Design Control requirements. Design validation testing has been performed to ensure that the modified device meets design specifications. The modified NxStage Therapy System has been compared to the NxStage Therapy System as cleared in K012510 and found to be substantial equivalent.

**Conclusion:**

Based on the device indications for use, comparison of descriptive and technological characteristics, and design control certification, the modified NxStage Therapy System has been shown to meet the minimum requirements that are considered acceptable for its intended use.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

APR 17 2002

Ms. Norma LeMay  
Sr. Regulatory Specialist  
NxStage Medical, Inc.  
439 S. Union St., Suite 501  
LAWRENCE MA 01843

Re: K020858  
Trade/Device Name: NxStage™ Therapy System  
Regulation Number: 21 CFR §876.5860  
Regulation Name: High permeability hemodialysis  
system  
Regulatory Class: II  
Product Code: 78 KDI  
Dated: March 15, 2002  
Received: March 18, 2002

Dear Ms. LeMay:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

Page 1 of 1

510(k) Number (if known): K020858

Device Name: NxStage Therapy System

Indications for Use:

The NxStage Therapy System is indicated for treatment of renal failure or fluid overload using hemofiltration and/or ultrafiltration. All treatments must be administered by a health care provider, under physician prescription.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

*David P. Legaspi*

**(Division Sign-Off)**  
**Division of Reproductive, Abdominal,**  
**and Radiological Devices**  
510(k) Number K020858

Prescription Use   
(Per 21 CFR 801.109)

OR

Over-the -Counter Use